viral infection in immunocompromised patients
Conditions
Interventions
Group A:Autogenous multivirus specific CTL cells cultured with IL-7 (IL-7/15/21) system
Group B:Autologous polyvirus-specific CTL cells were cultured with IL-2 (IL-2/12) system
Sponsors
Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients infected with immunodeficiency virus include patients infected with CMB, EBV, Adv, etc., including patients receiving immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation, solid organ transplantation, kidney disease, rheumatism disease and blood system disease. Patients were preferentially enrolled after allogeneic hematopoietic stem cell transplantation. 2. The expected survival time is 6 weeks or longer. 3. Patients who had previously received radiation therapy and had pulse oxygen saturation above 95% while breathing air. 4. Karlansky/Lansky score is greater than or equal to 50. 5. Bilirubin is less than or equal to 2x upper limit of normal, AST is less than 3x upper limit of normal, and hemoglobin is > 80g/L. 6. Creatinine below 2x upper limit of normal for age. 7. Patients should stop receiving other investigational therapy for at least 1 month before entering the study. 8. Patients should stop receiving traditional therapy, including rituximab, for at least 1 week before entering the study. 9. Patient has been fully informed of the risks and benefits of participating in the study and can sign the informed consent by patient and/or parent/guardian.
Exclusion criteria
Exclusion criteria: 1. Antithymocyte globulin (ATG) infusion was used within 4 weeks for transplant recipients; 2. Grade II or above acute graft-versus-host disease within 1 week of infusion; 3. Prednisone > 1 mg/kg body weight or equivalent for recipients; 4. Patients enrolled in other clinical trials within 3 months; 5. Previous history of malignant tumor; 6. For pregnant or lactating patients, serum or urine pregnancy test was performed before transfusion, and the test result was positive; 7. Other conditions deemed unsuitable for participation in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serological detection of virus; | — |
Countries
China
Contacts
Public ContactZhou Li
Anhui Provincial Hospital
Outcome results
None listed